16636217

Source:http://linkedlifedata.com/resource/pubmed/id/16636217

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0717758, umls-concept:C0948265, umls-concept:C1280500
pubmed:issue	8
pubmed:dateCreated	2006-4-25
pubmed:abstractText	Adipose-derived cytokines, including tumor necrosis factor alpha, may contribute to the inflammation that occurs in the metabolic syndrome. We investigated the effects of inhibition of tumor necrosis factor alpha with etanercept in patients with the metabolic syndrome.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/F32 DK068902-01, http://linkedlifedata.com/resource/pubmed/grant/M01-RR01066, http://linkedlifedata.com/resource/pubmed/grant/P30 DK040561-11
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372440
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adiponectin, http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers, http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G, http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins, http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0003-9926
pubmed:author	pubmed-author:BernsteinL ElizabethLE, pubmed-author:BerryJacquelineJ, pubmed-author:CanavanBridgetB, pubmed-author:GrinspoonSteven KSK, pubmed-author:KimSunnieS
pubmed:issnType	Print
pubmed:day	24
pubmed:volume	166
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	902-8
pubmed:dateRevised	2011-10-19
pubmed:meshHeading	pubmed-meshheading:16636217-Adiponectin, pubmed-meshheading:16636217-Adolescent, pubmed-meshheading:16636217-Adult, pubmed-meshheading:16636217-Biological Markers, pubmed-meshheading:16636217-Body Composition, pubmed-meshheading:16636217-C-Reactive Protein, pubmed-meshheading:16636217-Dose-Response Relationship, Drug, pubmed-meshheading:16636217-Female, pubmed-meshheading:16636217-Follow-Up Studies, pubmed-meshheading:16636217-Humans, pubmed-meshheading:16636217-Immunoglobulin G, pubmed-meshheading:16636217-Immunologic Factors, pubmed-meshheading:16636217-Injections, Subcutaneous, pubmed-meshheading:16636217-Male, pubmed-meshheading:16636217-Metabolic Syndrome X, pubmed-meshheading:16636217-Middle Aged, pubmed-meshheading:16636217-Receptors, Tumor Necrosis Factor, pubmed-meshheading:16636217-Recombinant Fusion Proteins, pubmed-meshheading:16636217-Retrospective Studies, pubmed-meshheading:16636217-Treatment Outcome
pubmed:year	2006
pubmed:articleTitle	Effects of etanercept in patients with the metabolic syndrome.
pubmed:affiliation	Program in Nutritional Metabolism and the Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Research Support, N.I.H., Extramural